Noticias de DNLI_US

Noticias del mercado

Últimas noticias sobre DNLI_US — 213 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: DNLI_US ✕ 213 resultados
25/03/2026 DNLI_US — Stock Titan
FDA clears Denali (NASDAQ: DNLI) AVLAYAH therapy for Hunter syndrome
25/03/2026 DNLI_US — TipRanks
Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy
25/03/2026 DNLI_US — Bitget
Denali Therapeutics Inc. announced that its new drug Avlayah will soon be available on the US market after receiving regulatory approval.
25/03/2026 DNLI_US — BioWorld News
Early FDA wins: Corcept’s Lifyorli, Denali’s Avlayah
25/03/2026 DNLI_US — Investing.com
FDA approves Denali’s Hunter syndrome brain therapy AVLAYAH
25/03/2026 DNLI_US — Taiwan News ES ← EN
Denali Therapeutics anuncia la aprobación de la FDA de EE. UU. de AVLAYAH™ (tividenofusp alfa-eknm) para el tratamiento del síndrome de Hunter (MPS II)
25/03/2026 DNLI_US — Pharmacy Times
FDA Approves Tividenofusp alfa-eknm, Targeting Neurologic Manifestations of Hunter Syndrome
25/03/2026 DNLI_US — BioSpace
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
25/03/2026 DNLI_US — Quiver Quantitative
Denali Therapeutics Receives FDA Approval for AVLAYAH™, First New Treatment for Hunter Syndrome in Nearly 20 Years
24/03/2026 DNLI_US — DirectorsTalk Interviews
Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring a 56% Potential Upside in Biotech Innovation
17/03/2026 DNLI_US — DirectorsTalk Interviews
Denali Therapeutics (DNLI) Stock Analysis: Assessing a 60% Upside Potential in Neurodegenerative Therapies
16/03/2026 DNLI_US — BioSpace
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection
13/03/2026 DNLI_US — Yahoo Finance
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed?

Página 11 de 11

keyboard_arrow_up